Guest guest Posted January 28, 2011 Report Share Posted January 28, 2011 Respected members, Supporting factors are: 1.Once in life time testing. Cost is going to fall after some time. 2. Haplotype study (HapMap) is showing promising results. 3. FDA is planning to specify guidelines for diagnostic tests for genetic testing. 4.Patients have to be counseled properly that genetic tests are nothing more than normal blood tests and the tests are meant to help them. Regards, Dr. Amruta Dawari JR 1, Dept of pharmacology, GMCH, Nagpur. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 28, 2011 Report Share Posted January 28, 2011 Respected members, Pharmacogenomics & clinical trial: The 2 most important for new drug development are efficacy & safety. With the availability of pharmacogenomics attrition of drug compound during clinical trial can be significantly reduced.This translates into reduction in loss of financial resources for drug development. Also the information can help in selecting appropriate patient for phaseI, phase II clinical trial; it can also help in preventing side effects and abrupt termination of clinical trial. Regards, Dr. Amruta Dawari JR 1, Dept of pharmacology, GMCH, Nagpur. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 28, 2011 Report Share Posted January 28, 2011 Respected members, Different issues arise with pharmacogenomics as Research issue: 1) Narrower target population could exclude those who might also benefit from therapies. 2) Evaluating therapies in smaller, targeted trials might miss critical, albeit rare, adverse drug events. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 28, 2011 Report Share Posted January 28, 2011 Respected members, There are clinical issues in front of clinicians like 1) Who should be offered testing? 2)What training or certification should be required to administer, interpret and explain tests? 3)How should tests be integrated into the current standard of care Regards, Dr. Amruta Dawari JR 1, Dept of pharmacology, GMCH, Nagpur. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 28, 2011 Report Share Posted January 28, 2011 Social issues in relation to pharmacogenomics are, • Preventing discrimination during giving -Insurance -Jobs -Educational opportunities on the basis of pharmacogenomics. There is need of legal implications: Regulation Enforcement Prosecution Restitution Regards, Dr. Amruta Dawari JR 1, Dept of pharmacology, GMCH, Nagpur. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 28, 2011 Report Share Posted January 28, 2011 Respected members, Economical issues in relation to pharmacogenomics are Unknown Costs of : 1)Pharmacogenomics testing 2)Unnecessary preventative interventions by individuals (e.g., surgery, prophylaxis, etc.) Regards, Dr. Amruta Dawari JR 1, Dept of pharmacology, GMCH, Nagpur. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.